You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

CLINICAL TRIALS PROFILE FOR AKINETON


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for AKINETON

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00495183 ↗ Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence Unknown status Hospital Universitari Vall d'Hebron Research Institute Phase 4 2009-01-01 The aim of this study is to assess the efficacy of caffeine compared to placebo as a maintenance treatment for cocaine dependence. Caffeine potentiation with biperiden will be also studied. Ninety patients with snorted/sniffed cocaine dependence will be randomized to receive caffeine (300 - 1200 mg t.i.d.) plus biperidene (8 mg b.i.d.) caffeine (300 - 1200 mg t.i.d.) with placebo or placebo during 10 days in an in-hospital setting.
NCT01048138 ↗ Use of Biperiden for the Prevention of Post-traumatic Epilepsy Recruiting Cristália Produtos Químicos Farmacêuticos Ltda. Phase 3 2018-01-31 There is no AED or medication that has been demonstrated to affect the development of post-traumatic epilepsy. Biperiden is a cholinergic antagonist, acting in the muscarinic receptor, that is widely used as an anti Parkinson drug. The investigators data with animal models of epilepsy indicate that anti-muscarinic agents might affect the natural course of the disease in the case of post-traumatic epilepsy.
NCT01048138 ↗ Use of Biperiden for the Prevention of Post-traumatic Epilepsy Recruiting University of Sao Paulo Phase 3 2018-01-31 There is no AED or medication that has been demonstrated to affect the development of post-traumatic epilepsy. Biperiden is a cholinergic antagonist, acting in the muscarinic receptor, that is widely used as an anti Parkinson drug. The investigators data with animal models of epilepsy indicate that anti-muscarinic agents might affect the natural course of the disease in the case of post-traumatic epilepsy.
NCT01048138 ↗ Use of Biperiden for the Prevention of Post-traumatic Epilepsy Recruiting Federal University of São Paulo Phase 3 2018-01-31 There is no AED or medication that has been demonstrated to affect the development of post-traumatic epilepsy. Biperiden is a cholinergic antagonist, acting in the muscarinic receptor, that is widely used as an anti Parkinson drug. The investigators data with animal models of epilepsy indicate that anti-muscarinic agents might affect the natural course of the disease in the case of post-traumatic epilepsy.
NCT04945213 ↗ Biperiden Trial for Epilepsy Prevention Not yet recruiting Ministry of Health, Brazil Phase 3 2022-02-01 One of the most important neurological consequences following Traumatic Brain Injury (TBI) is the development of post traumatic epilepsy (PTE). Nevertheless, there is still no effective therapeutic intervention to reduce the occurrence of PTE. In previous studies with animals models of epilepsy, the biperiden decreased the incidence and intensity of spontaneous epileptic seizures besides delaying their appearance. The aim of this study is the evaluation of biperiden as antiepileptogenic drug to prevent PTE and also the determination of side effects, evaluating its cost-effectiveness in patients with moderate and severe TBI.
NCT04945213 ↗ Biperiden Trial for Epilepsy Prevention Not yet recruiting PROADI-SUS Phase 3 2022-02-01 One of the most important neurological consequences following Traumatic Brain Injury (TBI) is the development of post traumatic epilepsy (PTE). Nevertheless, there is still no effective therapeutic intervention to reduce the occurrence of PTE. In previous studies with animals models of epilepsy, the biperiden decreased the incidence and intensity of spontaneous epileptic seizures besides delaying their appearance. The aim of this study is the evaluation of biperiden as antiepileptogenic drug to prevent PTE and also the determination of side effects, evaluating its cost-effectiveness in patients with moderate and severe TBI.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for AKINETON

Condition Name

Condition Name for AKINETON
Intervention Trials
Post Traumatic Epilepsy 1
Traumatic Brain Injury 1
Acute Brain Injury 1
Brain Injuries 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for AKINETON
Intervention Trials
Wounds and Injuries 2
Epilepsy, Post-Traumatic 2
Brain Injuries, Traumatic 2
Brain Injuries 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for AKINETON

Trials by Country

Trials by Country for AKINETON
Location Trials
Brazil 2
Spain 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for AKINETON

Clinical Trial Phase

Clinical Trial Phase for AKINETON
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for AKINETON
Clinical Trial Phase Trials
Recruiting 1
Unknown status 1
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for AKINETON

Sponsor Name

Sponsor Name for AKINETON
Sponsor Trials
Cristália Produtos Químicos Farmacêuticos Ltda. 1
University of Sao Paulo 1
Federal University of São Paulo 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for AKINETON
Sponsor Trials
Other 6
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.